Associated Papers
Exceptional sustained long-term complete response to Tepotinib in a MET-amplified advanced intrahepatic biliary tract cancer failing Durvalumab plus Cisplatin and Gemcitabine.
Reichinger A et al.
The Oncologist, 2024
Select a paper to view details